Kayne Anderson Rudnick Investment Management
VRTX icon

Kayne Anderson Rudnick Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.29M Sell
12,660
-425
-3% -$188K 0.02% 264
2026
Q1 		$5.84M Buy
13,085
+1,440
+12% +$671K 0.02% 257
2025
Q4 		$5.28M Buy
11,645
+26
+0.2% +$11.2K 0.01% 258
2025
Q3 		$4.55M Sell
11,619
-394
-3% -$165K 0.01% 273
2025
Q2 		$5.35M Sell
12,013
-221
-2% -$102K 0.01% 258
2025
Q1 		$5.93M Sell
12,234
-40
-0.3% -$18.6K 0.01% 260
2024
Q4 		$4.94M Sell
12,274
-827
-6% -$383K 0.01% 267
2024
Q3 		$6.09M Sell
13,101
-325
-2% -$156K 0.01% 262
2024
Q2 		$6.29M Sell
13,426
-293
-2% -$127K 0.02% 268
2024
Q1 		$5.73M Sell
13,719
-483
-3% -$204K 0.01% 281
2023
Q4 		$5.78M Sell
14,202
-561
-4% -$207K 0.01% 279
2023
Q3 		$5.13M Sell
14,763
-111
-0.7% -$38.8K 0.01% 286
2023
Q2 		$5.23M Sell
14,874
-223
-1% -$75.1K 0.01% 288
2023
Q1 		$4.76M Buy
15,097
+4
+0% +$1.2K 0.01% 295
2022
Q4 		$4.36M Sell
15,093
-639
-4% -$195K 0.01% 305
2022
Q3 		$4.55M Buy
15,732
+15,722
+157,220% +$4.52M 0.02% 290
2022
Q2 		$3K Sell
10
-26
-72% -$6.96K ﹤0.01% 577
2022
Q1 		$9K Buy
36
+26
+260% +$6.17K ﹤0.01% 541
2021
Q4 		$2K Hold
10
– – ﹤0.01% 592
2021
Q3 		$2K Hold
10
– – ﹤0.01% 559
2021
Q2 		$2K Hold
10
– – ﹤0.01% 550
2021
Q1 		$2K Hold
10
– – ﹤0.01% 546
2020
Q4 		$2K Hold
10
– – ﹤0.01% 557
2020
Q3 		$3K Sell
10
-17
-63% -$4.69K ﹤0.01% 497
2020
Q2 		$8K Hold
27
– – ﹤0.01% 444
2020
Q1 		$6K Hold
27
– – ﹤0.01% 451
2019
Q4 		$6K Buy
27
+10
+59% +$2.02K ﹤0.01% 449
2019
Q3 		$3K Hold
17
– – ﹤0.01% 489
2019
Q2 		$3K Buy
+17
New +$2.97K ﹤0.01% 484

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's VRTX Position: Q2 2026 in Review

Kayne Anderson Rudnick Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q2 2026, selling an estimated $188K and leaving 12,660 shares worth $6.29M. The position accounts for 0.02% of the portfolio, ranked #264.

Kayne Anderson Rudnick Investment Management first reported a position in VRTX in Q2 2019 and has held it in 29 quarters since. The position peaked at $6.29M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Kayne Anderson Rudnick Investment Management held 12,660 shares of Vertex Pharmaceuticals worth $6.29M as of Q2 2026.
  • Kayne Anderson Rudnick Investment Management sold 425 Vertex Pharmaceuticals shares in Q2 2026, an estimated $188K.
  • Vertex Pharmaceuticals made up 0.02% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #264 holding.
  • Kayne Anderson Rudnick Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Kayne Anderson Rudnick Investment Management's Vertex Pharmaceuticals position peaked at $6.29M in Q2 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.